Alpha particles as radiopharmaceuticals in the treatment of bone metastases : mechanism of action of radium-223 chloride (Alpharadin) and radiation protection
Approximately 85% to 90% of men with castration-resistant prostate cancer (CRPC) have radiological evidence of bone metastases. To date, however, therapies to manage bone metastases have been primarily palliative. Among CRPC patients with bone metastases, there is a significant unmet need for active antitumor treatment options that are highly efficacious and have a favorable safety profile. This article will present current information about alpha-pharmaceuticals, a new class of targeted cancer therapy for the treatment of patients with CRPC and bone metastases. It will review preclinical and clinical studies of the experimental radiopharmaceutical radium-223 chloride (Alpharadin), a first-in-class, highly targeted and well-tolerated alpha-pharmaceutical under development to improve survival in patients with bone metastases from advanced prostate cancer. Alpharadin kills cancer cells via alpha radiation from the decay of radium-223, a calcium mimetic that naturally self-targets to bone metastases. The mechanism of action of Alpharadin and specifics of administration, radiation protection, and patient management will be discussed.
| Errataetall: |
CommentIn: Oncology (Williston Park). 2012 Apr;26(4):342, 344. - PMID 22655526 |
|---|---|
| Medienart: |
Artikel |
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Oncology (Williston Park, N.Y.) - 26(2012), 4 vom: 11. Apr., Seite 330-7, 341 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cheetham, Philippa J [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 19.07.2012 Date Revised 21.11.2013 published: Print CommentIn: Oncology (Williston Park). 2012 Apr;26(4):342, 344. - PMID 22655526 Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM21826903X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM21826903X | ||
| 003 | DE-627 | ||
| 005 | 20231224040003.0 | ||
| 007 | tu | ||
| 008 | 231224s2012 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0727.xml |
| 035 | |a (DE-627)NLM21826903X | ||
| 035 | |a (NLM)22655525 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cheetham, Philippa J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Alpha particles as radiopharmaceuticals in the treatment of bone metastases |b mechanism of action of radium-223 chloride (Alpharadin) and radiation protection |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 19.07.2012 | ||
| 500 | |a Date Revised 21.11.2013 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Oncology (Williston Park). 2012 Apr;26(4):342, 344. - PMID 22655526 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Approximately 85% to 90% of men with castration-resistant prostate cancer (CRPC) have radiological evidence of bone metastases. To date, however, therapies to manage bone metastases have been primarily palliative. Among CRPC patients with bone metastases, there is a significant unmet need for active antitumor treatment options that are highly efficacious and have a favorable safety profile. This article will present current information about alpha-pharmaceuticals, a new class of targeted cancer therapy for the treatment of patients with CRPC and bone metastases. It will review preclinical and clinical studies of the experimental radiopharmaceutical radium-223 chloride (Alpharadin), a first-in-class, highly targeted and well-tolerated alpha-pharmaceutical under development to improve survival in patients with bone metastases from advanced prostate cancer. Alpharadin kills cancer cells via alpha radiation from the decay of radium-223, a calcium mimetic that naturally self-targets to bone metastases. The mechanism of action of Alpharadin and specifics of administration, radiation protection, and patient management will be discussed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Radiopharmaceuticals |2 NLM | |
| 650 | 7 | |a Radium |2 NLM | |
| 650 | 7 | |a W90AYD6R3Q |2 NLM | |
| 700 | 1 | |a Petrylak, Daniel P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncology (Williston Park, N.Y.) |d 1989 |g 26(2012), 4 vom: 11. Apr., Seite 330-7, 341 |w (DE-627)NLM012602825 |x 0890-9091 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2012 |g number:4 |g day:11 |g month:04 |g pages:330-7, 341 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2012 |e 4 |b 11 |c 04 |h 330-7, 341 | ||